I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Derek Jantz Biography and Net Worth

Insider of Precision BioSciences

Derek Jantz is the Chief Scientific Officer of Precision BioSciences. He co-founded the company in 2006 after co-inventing a novel method for modifying the DNA-recognition properties of the I-CreI homing endonuclease. This early work is the foundation of Precision’s ARCUS genome editing platform, which has been used to develop clinical-stage oncology therapeutics as well as a robust pipeline of pre-clinical cell and gene therapies. Trained as a protein engineer, Derek was an early developer of zinc finger technology and spent most of his research career designing proteins for genome editing applications. At Precision, Derek is responsible for all research programs and also supports business and corporate development. He serves on the senior leadership team and is a member of the board of directors. When he is not making critical decisions, Derek enjoys writing holiday themed poetry and finding ways to slip sci-fi references into corporate presentations.

What is Derek Jantz's net worth?: The estimated net worth of Derek Jantz is at least $638,011.84 as of June 8th, 2022. Dr. Jantz owns 135,172 shares of Precision BioSciences stock worth more than $638,012 as of December 22nd. This net worth approximation does not reflect any other investments that Dr. Jantz may own. Learn More about Derek Jantz's net worth.
How do I contact Derek Jantz?: The corporate mailing address for Dr. Jantz and other Precision BioSciences executives is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. Precision BioSciences can also be reached via phone at (919) 314-5512 and via email at [email protected]. Learn More on Derek Jantz's contact information.
Has Derek Jantz been buying or selling shares of Precision BioSciences?: Derek Jantz has not been actively trading shares of Precision BioSciences during the last ninety days. Most recently, Derek Jantz sold 628 shares of the business's stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $61.80, for a transaction totalling $38,810.40. Following the completion of the sale, the insider now directly owns 135,172 shares of the company's stock, valued at $8,353,629.60. Learn More on Derek Jantz's trading history.
Who are Precision BioSciences' active insiders?: Precision BioSciences' insider roster includes Derek Jantz (Insider), Matthew Kane (CEO), and David Thomson (COO). Learn More on Precision BioSciences' active insiders.
Are insiders buying or selling shares of Precision BioSciences?: In the last twelve months, insiders at the sold shares 10 times. They sold a total of 11,350 shares worth more than $113,740.03. The most recent insider tranaction occured on November, 4th when CEO Michael Amoroso sold 3,012 shares worth more than $24,668.28. Insiders at Precision BioSciences own 4.0% of the company. Learn More about insider trades at Precision BioSciences.
Information on this page was last updated on 11/4/2024.

Derek Jantz Insider Trading History at Precision BioSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/8/2022	Sell	628	$61.80	$38,810.40	135,172
5/17/2021	Sell	666	$281.40	$187,412.40	134,409
5/12/2021	Sell	322	$261.60	$84,235.20	134,609
4/19/2021	Sell	322	$260.70	$83,945.40	134,214
3/17/2021	Sell	322	$327.60	$105,487.20	132,240
2/19/2021	Sell	322	$346.50	$111,573.00	130,961
1/29/2021	Sell	214	$367.50	$78,645.00	130,459
1/27/2021	Sell	234	$350.40	$81,993.60	129,475

Derek Jantz Buying and Selling Activity at Precision BioSciences

Precision BioSciences Company Overview

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Today's Range

Now: $4.72

$4.51

$5.01

50 Day Range

MA: $7.31

$4.13

$9.02

2 Week Range

Now: $4.72

$4.13

$19.43

Volume

705,308 shs

Average Volume

83,579 shs

Market Capitalization

$36.21 million

P/E Ratio

78.68

Dividend Yield

N/A

Beta

1.41

I was wrong. Dead wrong.

From Porter & Company | Ad